HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Lower 900 mcg dose of albinterferon alfa-2b is on track for hepatitis C filing in fall 2009, Human Genome Sciences says.